{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:26:47Z","timestamp":1792794407283,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ethics Committee on Human Research of the Federal University of Santa Catarina","id":[{"id":"https:\/\/ror.org\/041akq887","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n To determine the benefit of a tetrahydrocannabinol (THC)-rich cannabis oil on symptoms and quality of life of fibromyalgia patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A double-blind, randomized, placebo-controlled clinical trial was conducted for eight weeks to determine the benefit of a THC-rich cannabis oil (24.44\u2009mg\/mL of THC and 0.51\u2009mg\/mL of cannabidiol [CBD]) on symptoms and quality of life of 17 women with fibromyalgia, residents of a neighborhood with a low socioeconomic profile and a high incidence of violence in the city of Florianopolis, Brazil. The initial dose was one drop (\u223c1.22\u2009mg of THC and 0.02\u2009mg of CBD) a day with subsequent increases according to symptoms. The Fibromyalgia Impact Questionnaire (FIQ) was applied at pre- and postintervention moments and in five visits over eight weeks.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were no significant differences on baseline FIQ score between groups. However, after the intervention, the cannabis group presented a significant decrease in FIQ score in comparison with the placebo group (P\u2009=\u20090.005) and in comparison with cannabis group baseline score. (P\u2009&lt;\u20090.001). Analyzing isolated items on the FIQ, the cannabis group presented significant improvement on the \u201cfeel good,\u201d \u201cpain,\u201d \u201cdo work,\u201d and \u201cfatigue\u201d scores. The placebo group presented significant improvement on the \u201cdepression\u201d score after intervention. There were no intolerable adverse effects.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Phytocannabinoids can be a low-cost and well-tolerated therapy to reduce symptoms and increase the quality of life of patients with fibromyalgia. Future studies are still needed to assess long-term benefits, and studies with different varieties of cannabinoids associated with a washout period must be done to enhance our knowledge of cannabis action in this health condition.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/pm\/pnaa303","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T15:44:26Z","timestamp":1596815066000},"page":"2212-2218","source":"Crossref","is-referenced-by-count":89,"title":["Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A\u00a0Randomized, Double-Blind, Placebo-Controlled Clinical Trial"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9901-8646","authenticated-orcid":false,"given":"Carolina","family":"Chaves","sequence":"first","affiliation":[{"name":"Public Health School, Municipal Health Secretary, Florianopolis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Cesar T","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Santa Catarina, Florianopolis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Pelegrini","sequence":"additional","affiliation":[{"name":"Department of Physical Education, Santa Catarina State University, Florianopolis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"issue":"5","key":"2020102904115870900_pnaa303-B1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/RHU.0000000000000702","article-title":"Medical cannabis for the treatment of fibromyalgia","volume":"24","author":"Habib","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"2020102904115870900_pnaa303-B2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.rbr.2016.07.003","article-title":"EpiFibro (Brazilian Fibromyalgia Registry): Data on the ACR classification and diagnostic preliminary criteria fulfillment and the follow-up evaluation","volume":"57","author":"Martinez","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"4","key":"2020102904115870900_pnaa303-B3","doi-asserted-by":"crossref","first-page":"e18440","DOI":"10.1371\/journal.pone.0018440","article-title":"Cannabis use in patients with fibromyalgia: Effect on symptoms relief and health-related quality of life","volume":"6","author":"Fiz","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"2020102904115870900_pnaa303-B4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2020102904115870900_pnaa303-B5","volume-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","year":"2017"},{"issue":"1","key":"2020102904115870900_pnaa303-B6","first-page":"21","article-title":"Can\u00e1bis e\u00a0canabin\u00f3ides para fins medicinais","volume":"11","author":"Correia-da-Silva","year":"2019","journal-title":"Rev Portuguesa Farmacoterapia"},{"issue":"5","key":"2020102904115870900_pnaa303-B7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020102904115870900_pnaa303-B8","first-page":"528952","article-title":"Classification and clinical diagnosis of fibromyalgia syndrome: Recommendations of recent","volume":"2013","year":"2013","journal-title":"Evid Based Complement Altern Med"},{"key":"2020102904115870900_pnaa303-B9"},{"key":"2020102904115870900_pnaa303-B10","first-page":"24","article-title":"Valida\u00e7\u00e3o da vers\u00e3o Brasileira do Fibromyalgia Impact Questionaire (FIQ)","volume":"46","year":"2006","journal-title":"Rev Bras Reumatol"},{"issue":"5","key":"2020102904115870900_pnaa303-B11","first-page":"728","article-title":"The Fibromyalgia Impact Questionnaire: Development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol"},{"issue":"3","key":"2020102904115870900_pnaa303-B12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0002-9343(01)01089-0","article-title":"A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia","volume":"112","author":"Arnold","year":"2002","journal-title":"Am J Med"},{"issue":"7","key":"2020102904115870900_pnaa303-B13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9343(03)00116-5","article-title":"Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study","volume":"114","author":"Bennett","year":"2003","journal-title":"Am J Med"},{"issue":"11","key":"2020102904115870900_pnaa303-B14","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1345\/aph.1D112","article-title":"Venlafaxine treatment of fibromyalgia","volume":"37","author":"Sayar","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2020102904115870900_pnaa303-B15","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2020102904115870900_pnaa303-B16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DHPS.S95535","article-title":"Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia","volume":"8","author":"Bhusal","year":"2016","journal-title":"Drug Healthc Patient Saf"},{"issue":"2","key":"2020102904115870900_pnaa303-B17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","article-title":"Nabilone for the treatment of pain in fibromyalgia","volume":"9","author":"Skrabek","year":"2008","journal-title":"J Pain"},{"issue":"7","key":"2020102904115870900_pnaa303-B18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079906X112651","article-title":"Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief","volume":"22","author":"Schley","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2020102904115870900_pnaa303-B19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","article-title":"An experimental randomized study on the analgesic effects of","volume":"160","year":"2019","journal-title":"Pain"},{"key":"2020102904115870900_pnaa303-B20","volume-title":"Chronical of WHO","year":"1947"},{"issue":"1","key":"2020102904115870900_pnaa303-B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/neu.20080","article-title":"The endogenous cannabinoid system and its role in nociceptive behavior","volume":"61","author":"Cravatt","year":"2004","journal-title":"J Neurobiol"},{"issue":"1\u20132","key":"2020102904115870900_pnaa303-B22","first-page":"31","article-title":"Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?","volume":"25","author":"Russo","year":"2004","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"2020102904115870900_pnaa303-B23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/can.2016.0009","article-title":"Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other","volume":"1","author":"Russo","year":"2016","journal-title":"Cannabis Cannabinoid Res"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/21\/10\/2212\/34050789\/pnaa303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/21\/10\/2212\/34050789\/pnaa303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T04:15:59Z","timestamp":1603944959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/21\/10\/2212\/5942556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,28]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnaa303","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,10,1]]}}}